Welcome!

The IG MedCann is the association of Swiss manufacturers of cannabis medicines. We aim to create a safe and sustainable market for medical cannabis in Switzerland through high-quality products, secure supply, clear regulations, and improved access for patients.

IG MedCann has supported the politically initiated effort for the SIMPLIFIED DISPENSING OF MEDICINAL CANNABIS. Since August 2022, all patients now have access to cannabis medications whenever their treating physician deems it appropriate, without the need for a special permit from the Federal Office of Public Health (BAG).

IG MedCann is committed to working alongside patient organizations, medical societies, pharmacy associations, authorities, and health insurance companies to help shape a favorable environment for cannabis medicine. Cannabis medications should be researched, manufactured, prescribed, used, and reimbursed according to the highest standards.

IG MedCann is a board member of the SGCM (the Swiss Society for Cannabis in Medicine) and is actively involved in various areas, particularly in politics and law. An important objective for IG MedCann and the SGCM is to improve the currently limited reimbursement of the cannabis medications by the health insurance companies.

About us

Members

Four Swiss manufacturers of cannabis medications (Hänseler AG, Cannapharm AG, VitaPlant AG, and Spagyrik Produktions AG) founded IG MedCann in 2018. Currently, our members include Canexis, Cannapharm, CuraLeaf, Hänseler, Linnea, Medropharm, PhytoVitality, Pure Holding, Spagyrik Produkt., Pharmaserve, and Phytomed.

Here you can find the current statutes.

IG MedCann is a board member of the Swiss Society for Cannabis in Medicine (SGCM).

Our Goals

We aim to create a safe and sustainable market for medical cannabis in Switzerland through high-quality products, secure supply, clear regulations, and improved access for patients.

Our members are united in manufacturing cannabis medications that reach patients in the form of magistral prescriptions. Given the multitude of potential indications, it is crucial that the medication is marketable as a magistral prescription/recipe.

Germany recognized this necessity and, with a legal amendment in 2017, established a system that allows the dispensing of cannabis medications in the form of magistral prescriptions. Since the regulation change in August 2022, this is also possible in Switzerland.

A formal approval for a finished product typically includes only three or four indications. This creates a problem where doctors have to act off-label for many applications. Experience shows that cannabis medications have a very broad, partly undiscovered spectrum of applications.

Currently, it is optimal if the continuously growing knowledge about the applications allows the treating physician to determine for which specific condition the cannabis medication should be used.

What Are Cannabis medications?

We refer to processed forms of cannabis as cannabis medications, such as cannabis extracts, cannabis isolates (including dronabinol and CBD), and cannabis flowers. In particular, cannabis extracts and isolates allow for increased standardization of the relevant ingredients during manufacturing. Currently, we are talking about THC and CBD. In the future, the standardization of other important compounds of the cannabis plant will likely be added.

Contact

Write to us for a consultation or just to say hello, we look forward to hearing from you.